Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (141-150 of 193) with videos related to

Pageof 20
Sort By:
Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.
Cancer Cell|April 12, 2017
Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In VivoLuigi Leanza, Matteo Romio, Katrin Anne Becker, et al.
Leukemia & Lymphoma|January 11, 2025
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVDChiara Rusconi, Angelica Barone, Andrea Visentin, et al.
British Journal of Haematology|March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre studyNicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
British Journal of Haematology|April 4, 2018
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristicsGian Matteo Rigolin, Elena Saccenti, Emanuele Guardalben, et al.
Hemasphere|February 21, 2025
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemiaAnna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, et al.
American Journal of Hematology|June 29, 2023
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus studyAndrea Visentin, Francesca Romana Mauro, Lydia Scarfò, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Hematological Oncology|October 25, 2021
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experienceFulvio Massaro, Vincenzo Pavone, Piero Maria Stefani, et al.
Pageof 20

Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.
Cancer Cell|April 12, 2017
Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In VivoLuigi Leanza, Matteo Romio, Katrin Anne Becker, et al.
Leukemia & Lymphoma|January 11, 2025
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVDChiara Rusconi, Angelica Barone, Andrea Visentin, et al.
British Journal of Haematology|March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre studyNicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
British Journal of Haematology|April 4, 2018
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristicsGian Matteo Rigolin, Elena Saccenti, Emanuele Guardalben, et al.
Hemasphere|February 21, 2025
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemiaAnna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, et al.
American Journal of Hematology|June 29, 2023
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus studyAndrea Visentin, Francesca Romana Mauro, Lydia Scarfò, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Hematological Oncology|October 25, 2021
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experienceFulvio Massaro, Vincenzo Pavone, Piero Maria Stefani, et al.
Pageof 20